News

Currently, Precision is advancing its clinical trials with NEO-102, which is being developed as a therapeutic drug candidate for pancreatic and colorectal cancers. As part of the deal,

These new offerings will serve to further the company’s mission of providing innovative service solutions to a variety of businesses throughout the biotech, pharmaceutical, and medical device industries.

Collectively these engagements encompass cloud-based technologies and professional services and training across BioClinica’s full eClinical product suite: OnPoint CTMS, Express EDC, Trident IRT, and clinical supplies Optimizer. Under

The drug is indicated for the treatment of type 2 diabetes mellitus in adults, to improve glucose control as monotherapy, when diet and exercise alone do not provide

By using Oracle Health Sciences Network, Joslin joins a growing list of healthcare provider participants which will expand clinical trial research for its patients through real-time collaboration with

The deal is initially aimed at using the companies’ complementary scientific platforms within the framework of ongoing research projects. Both the firms will assess results achieved to date,

The deal will combine integrated components to allow clinicians to use genomic data generated by laboratories more easily and efficiently to discover targeted therapeutic options suitable for each

The company will use the funding to advance its second clinical program with a new TCR to enter the clinic in the UK. Biomedical Catalyst Fund’s £2.1m grant

Launched in January 2008 for secondary hyperparathyroidism (HPT) in patients who are undergoing regular dialysis, Regpara tablets 25mg and 75mg acts on calcium receptors on the parathyroid gland